Trial reportDrug design, development and therapy2025
The Recovery of Ciprofol, Remimazolam and Remimazolam-Flumazenil for General Anesthesia Undergoing Fundus Surgery: A Single-Center, Prospective, Randomized, Controlled Clinical Study.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of ciprofol on the incidence of postoperative delirium in adult surgical patients: a meta-analysis and meta-regression.Frontiers in neurologyPooled it
- Dexamethasone Alone versus Combined with Droperidol for Preventing Postoperative Nausea and Vomiting in Gynecological Day Surgery Under Ciprofol-Alfentanil Anesthesia: A Randomized Double-Blind Controlled Trial.Drug design, development and therapy · 2026Trial
- Comparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Effects of remimazolam on postanesthetic shivering and related clinical responses in patients undergoing cesarean section.Frontiers in medicine · 2026Trial
- The Impact of General Anesthetics on Postoperative Delirium: A Narrative Review Based on Clinical Randomized Controlled Trials from the Last Five Years.Geriatrics (Basel, Switzerland) · 2026Review
- Safety and efficacy of remimazolam in general anaesthesia during laparoscopic cholecystectomy: A systematic review and meta-analysis of randomised controlled trials.Indian journal of anaesthesia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Ciprofol (HSK3486 injectable emulsion) is a 2.6-disubstituted phenol derivative that acts similarly to propofol with a fast onset, quick, and stable recovery. Moreover, remimazolam is a new benzodiazepine with a faster onset and recovery than midazolam, and more stable hemodynamics than propofol. We found no relevant literature that directly compared these two drugs. The primary objective of this study was to compare the recovery of HSK3486 with that of remimazolam during successful general anesthesia. Patients and Methods: This prospective, randomized, double-blind study included 93 patients who had undergone fundus surgery. The patients were divided into three groups: HSK3486 (H group), remimazolam-saline Results: The RF group showed the shortest eye-opening time: 3.8 (2.8) min vs 13.3 (5.2) min for the H group, Conclusion: The incorporation of flumazenil with remimazolam for total intravenous anesthesia provided rapid and reliable recovery of consciousness, although there were no significant visible differences between HSK3486 and Remimazolam-saline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.